| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.057 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | indisulam | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |